Volume 94 Issue 44 | p. 17 | Concentrates
Issue Date: November 7, 2016

Lonza will supply Clovis drug

Department: Business
Keywords: pharmaceutical chemicals, Lonza, Clovis, oncology, PARP inhibitor

Contract manufacturer Lonza will build a plant in Visp, Switzerland, to supply rucaparib, the active ingredient in Clovis Oncology’s PARP inhibitor. Lonza will open a new production line in 2019 that will provide dedicated supply until 2025. Rucaparib targets cancer by inhibiting the DNA-repair enzymes poly-ADP ribose polymerase-1, 2, and 3. It is under FDA priority review for treating advanced ovarian cancer with a decision to come by February 2017.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment